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Prostate cancer in Asia 171. Introduction
Approximately 238,590 new cases of prostate cancer (PCa)
were diagnosed in the United States in 2013, causing 29,720
deaths in the same year [1]. During the past few decades,
PCa incidence was reported to be much lower in Asian
countries [2]; however, with dramatic economic growth and
socio-cultural changes leading to an increased life expec-
tancy and westernized lifestyle, the incidence andmortalityFigure 1 (A) Incidence and mortality rates (per 100,000) in Asian
(per 100,000) in different Asian regions in 2012. (C) Mortality/incid
rate, ASR). Data sources: GLOBOCAN 2012 v1.0, Cancer Incidencerates of PCa in some Asian countries have shown a rapidly
growing trend [2]. Currently PCa has already ranked the sixth
of the most frequent cancers in 2012 among Asian countries
[3]. As the aging process of the Asian population is still going
on and the benefits of economic development will continue
to accelerate lifestyle changes towards Westerners, PCa was
predicted to gradually become a more serious healthcare
and socio-economic issue. Meanwhile, the average spending
on healthcare in most Asian countries was still much lowercountries and regions in 2012. (B) Incidence and mortality rates
ence ratios in Asian countries and regions in 2012 (Age specific
and Mortality Worldwide: IARC Cancer Base No. 11 [Internet].
18 R. Chen et al.than that of Western countries [4]. Dealing with such a trend
of rapid growth of PCa with a limited budget in most Asian
countries is extremely challenging. Here in this report, we
not only systematically summarized currently available
data, but also collected the first-hand clinical statistics on
current diagnostic strategy and emerging treatment options
both in surgery management and castration-resistant pros-
tate cancer (CRPC) from Chinese Prostate Cancer Con-
sortium (CPCC) and leading urologists in Asian countries and
regions. These data are based on national registry data or
from representative/leading hospitals in situations where
the former is not available. Thus, cautions should be taken in
interpreting these data. Hopefully, we believe such infor-
mationwould be helpful in decisionmaking for urologists and
oncologists, healthcare ministries and medical researchers
from a clinical prospective.2. PCa epidemiology in Asia
2.1. Incidence
Globally, PCa is the second most common cancer in men and
the incidence varies more than 25-fold worldwide; the rates
are highest in Australia/New Zealand and Northern America
(age standardized rate (ASR) 111.6 and 97.2 per 100,000,
respectively), and in Western and Northern Europe [3].
However, after reaching its peak in mid-1900s which is
commonly attributed to the widespread use of prostate-
specific antigen (PSA) tests, the incidence of PCa in several
developed countries (Canada, the United States, United
Kingdom, Italy, etc.) has witnessed a decrement in the past
few years [5], but still remains higher than that in Asian
populations. According to the WHO report in 2012, the inci-
dence rates were estimated at 10.5% and 4.5% in East and
South-Central Asia, respectively [3] (Fig. 1A, B). However,
PCa incidence in Asian countries has been on a steady in-
crease during the past few decades. Currently, PCa has
already become the sixthmost frequent cancer in Asianmen,
with the highest inWestern Asia ranking second in all cancers
and the lowest in South-Central Asia ranking eighth.
2.2. Mortality
With an estimated 307,000 deaths in 2012, PCa is the fifth
leading cause of death from cancer in men globally (6.6% of
the total deaths in men). It is still controversy if PSA testing
had a significant influence on mortality rates. Less variation
in mortality rates was seen worldwide (10-fold from
approximately 3 to 30 per 100,000) than is observed for
incidence, with the number of deaths from PCa larger in
less developed than in more developed regions (165,000
and 142,000, respectively). The average mortality rate of
PCa in Asian countries is 3.8 per 100,000. In economically
developed regions such as Japan, Singapore, and Korea,
these rates are 5, 4.5, and 4.6 per 100,000, respectively
[3]. The trends of mortality rates were more variable; with
increasing trends observed in China (Hong Kong),
Kazakhstan, and Korea, decreasing trends seen in Israel,
Japan, Kyrgyzstan, and Uzbekistan, and rather stable
trends reported in Singapore and Tajikistan [3].2.3. Changing trend in epidemiology
As illustrated in a previous review [6], the PCa incidence in
developing East Asia countries has been on a rapid rise since
the 1990s. For instance, the incidence rate has grown at a
rate of 7.2% per year from 2004 to 2009. As the national
cancer registry report shows, the incidence was 9.92 per
100,000 in 2009 [7]. The incidence in Korea has also been on
a rapid rise from 8.4 per 100,000 in 1999 to 24.4 per 100,000
in 2011 [8]. Considering the similar genetic background
between Korea and China, it is predicted that the incidence
in China will increase to a level comparable to Korea if
China adopts a similar healthcare policy to Korea in PCa
detection. However, it is relatively difficult to predict if the
incidence will continue to surge in Korea and Japan where
this rate has already experienced rapid growth.
2.4. Mortality/incidence ratios
The MR/IR (mortality-to-incidence rate ratio) was as high as
40% in Asia compared to 18% in Europe, 10% in Northern
America and 25% worldwide. The lowest MR/IR rate was
witnessed in Israel, whereas it is typically much higher in
countries with unfavorable economic situations, like Viet-
nam and Iraq (Fig. 1C). In several developed countries like
Japan, Korea and Singapore, although the incidence is higher
than other countries, the MR/IR is relatively lower than in
that of several Southeast and West Asian countries [3].3. Risk factors for PCa in Asian men
3.1. Genetic differences in prostate cancer in Asian
men
Asians differ significantly with regards to race. East and
Southeast Asians share a similar genetic background and are
generally known as Mongolians; Northwest and Central
Asians are of Turkic, Iranian or Caucasian ethnicity. The
South Asians consist of mainly the Indian population which
has been considered as a mixed population of Caucasians
and Mongolians. As for the West Asian population, some of
them are Caucasians and others are Arabians.
There are two types of genetic variations that are
important in prostate carcinogenesis; one is somatic alter-
ation in prostate tumors, and the other is germline common
polymorphic conferring moderate-to-low risk for devel-
oping the disease. For the first type of genetic variation,
substantial racial differences have been reported. For
instance, the most prevalent gene fusion in Caucasians is
the TMPRSS2-ERG fusion, with a prevalence of about 50%.
However, much lower frequencies are reported in Asian
populations (8%e21%) [9,10]. Another prominent variation
is the PTEN inactivation in PCa patients. PTEN inactivation
was reported in 70% of Caucasians but only 34% in Chinese
patients [9,11]. Currently, there is evidence that PTEN loss
and TMPRSS2-ERG fusion are related [12]. This may offer a
potential explanation for the low incidence of PTEN loss
and low expression of TMPRSS2-ERG fusion in the East Asian
population. Other mutations, such as KRAS mutations and
BRAF copy number gain, are seen more frequently in Asian
Table 1 SNPs indentified in genome-wide association studies in Asian populations.
Locus SNP Nearby genes Reference allele Effect allele Effect OR (95%CI) Ethnic of identification Reference
2p24 rs13385191 C2orf43 A G 1.15 (1.10e1.21) Japanese [16]
5p15 rs12653946 IRX4 C T 1.26 (1.20e1.33) Japanese [16]
6p21 rs1983891 FOXP4 C T 1.15 (1.09e1.21) Japanese [16]
6q22 rs339331 RFX6 C T 1.22 (1.15e1.28) Japanese [16]
13q22 rs9600079 Unknown G T 1.18 (1.12e1.24) Japanese [16]
3p11 rs2055109 Unknown T C 1.20 (1.13e1.29) Japanese [17]
10q26 rs2252004 Unknown T G 1.16 (1.10e1.22) Japanese [17]
11q12 rs1938781 FAM111A T C 1.16 (1.11e1.21) Japanese [17]
9q31 rs817826 RAD23BeKLF4 T C 1.41 (1.29e1.54) Chinese [18]
19q13 rs103294 LILRA3 T C 1.28 (1.21e1.36) Chinese [18]
9p24 rs7045455 SMARCA2 T C 3.98 (1.97e8.05) Tunisians [19]
9p24 rs12686439 SMARCA2 G A 3.32 (1.80e6.15) Tunisians [19]
9p24 rs10810919 SMARCA2 T C 5.03 (2.22e11.4) Tunisians [19]
9p24 rs10963533 SMARCA2 T C 4.19 (2.01e8.75) Tunisians [19]
9p24 rs10963540 SMARCA2 G A 4.81 (2.23e10.4) Tunisians [19]
17q21 rs12601982 STAT5A A G 2.61 (1.67e4.07) Tunisians [19]
17q21 rs8078731 STAT3 A T 2.47 (1.55e3.93) Tunisians [19]
22q13 rs5750627 LOC646851 C T 2.40 (1.60e3.60) Tunisians [19]
22q13 rs6001173 LOC646851 C T 2.32 (1.54e3.49) Tunisians [19]
22q13 rs138702 SUN2 T A 2.44 (1.60e3.71) Tunisians [19]
22q13 rs138712 SUN2 A G 2.47 (1.63e3.76) Tunisians [19]
SNPs, single nucleotide polymorphisms; OR, odds ratio, CI, confidential interval.
Prostate cancer in Asia 19patients than in the Western population [13,14]. With the
help of the next generation of sequencing technologies,
more variations among races will be identified.
Single nucleotide polymorphisms (SNPs) are also
different between Asian and Western populations. Genome-
wide association studies (GWAS) have identified 76 suscep-
tibility loci associated with PCa risk [15]. Of these, some
loci have been validated in Asian population in GWAS and
validation studies. To date, three GWAS in Asians were re-
ported [16e18]. Ten SNPs were identified to be associated
with PCa in Japanese and Chinese and 11 SNPs in Tunisians
(Table 1). Findings of GWAS in East Asians identified a large
portion of SNPs that are identical with Westerners, with
some unique SNPs identified. However, reports from GWAS
in Arabian populations indicated a relatively large number
of SNPs that are different from previous findings [19].
Such differences in PCa risk-associated SNPs may suggest
distinct mechanisms in the development of PCa against
different ethnic groups. More importantly and from a clin-
ical relevant point of view, these discrepancies will even-
tually influence the onset, diagnosis, prognosis and
treatment of PCa in the Asian populations.3.2. Lifestyle changes and PCa in Asian populations
Genetic variations aside, environmental differences may
act as an important factor for PCa as well. Asian pop-
ulations vary greatly on diet and lifestyles. Generally, East
and Southeast Asians consume more vegetables, with a
lower proportion of animal protein and high-fat food in
their daily intake than Western populations [20]. However,
the situation has been changing during these past few de-
cades due to economic development.Firstly, Asian men who immigrate to foreign countries
may display a different epidemiologic pattern. For instance,
the PCa incidence of Indians who immigrate to Singapore, UK
and US were higher compared to Indians in India (9.9, 33.7,
47.4 and 4.6 per 100,000, respectively) [21]. Although the
low rate in India may be partially due to under-diagnosis,
they may also be due to lifestyle and environmental fac-
tors. Secondly, per capita consumption of animal fat in Asian
countries has been on an increasing trend sincemore than 40
years ago. From the 1960s to the 2000s, consumption of an-
imal fat increased by 591.7%, 578.6%, and 128.6%, respec-
tively in Chinese, Korean and Japanese populations [22]. In
these countries, nutrition transition played a role in the
increasing incidence of colon cancer and PCa during the past
few decades. Thirdly, environmental factors, particularly in
countries with a Western diet, will keep a relatively high
speed of increase in incidence. Other factors are mainly
clinical, for example, the variation in access to PSA
screening and physicians. All of these might be major
contributing factors. In this aspect, incidence in China and
India will probably increase substantially owning to the
economic development and rapid lifestyle changes [22].
Meanwhile, countries like Japan, Korea and Israel that have
a developed economy and a relatively stable lifestyle may
present a more stable trend in incidence.
4. Diagnosis of prostate cancer in Asian
countries
4.1. PSA-based screening in Asian countries
National PSA screening programs were not carried out in
Asian countries, partially due to the lower incidence rate
Table 2 Reported age-specific PSA cut-off values for Asian population.
Study Country or region Ref. Cases PSA 95%CI (ng/mL)
<40 40e49 50e59 60e69 70e79 >80
Oesterling et al., 1993 United States [28] 471 e 2.5 3.5 4.5 6.5 e
Liu et al., 2008 Mainland, China [25] 8422 e 2.15 3.2 4.1 5.37 e
Lin et al., 2004 Taiwan, China [27] 1008 1.85 2.59 3.31 5.03 5.73 e
Wu and Huang, 2004 Taiwan, China [29] 1236 e e 4.0 6.0 6.0 e
Choi et al., 2007 Korea [30] 286 1.85 1.92 2.37 3.56 5.19 e
Oesterling et al., 1995 Japan [31] 335 e 2 3 4 5 e
Imai et al., 1995 Japan [32] 3526 e 2.1 2.9 4.0 5.2 5.9
Malati and Kumari, 2004 India [33] 583 0.9 1.3 1.48 1.6 2 2.47
Abdrabo, 2011 Sudanese [34] 1051 e 3 3.02 3.8 8.7 (70e90)
Kamal et al., 2003 Saudi Arabia [35] 567 1.03 1.62 2.09 2.86 3.17
Saw and Aw, 2000 Singapore [36] 513 1.4 1.7 2.3 4 6.3 6.6
Lim et al., 2014 Malay [26] 378 e 0.6 1 1.2 1.4 e
Kehinde et al., 2005 Kuwait and Oman [37] 396 e 0.9 1.6 2.9 5.5 e
Khezri et al., 2009 Iran [38] 930 e e 2.61 3.59 4.83 e
PSA, prostate-specific antigen; Ref., reference; CI, confidential interval.
20 R. Chen et al.and/or the inadequate financial resources for healthcare in
some Asian countries. On a global scale, PCa screening re-
mains controversial. The updated results from the Prostate,
Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)
did not illustrate a mortality benefit for PSA screening [23].
The European Randomized Study of Screening for Prostate
Cancer (ERSPC) demonstrated a 21% reduction in PCa-
specific mortality in favor of screening [24]. In most Asian
countries, financial consideration has always been a keyFigure 2 PSA distributions of patients who underwent biopsies in
China: Chinese Prostate Cancer Consortium (CPCC) statistics; Hong
Chinese University of Hong Kong) university hospitals; Singapore: R
General Hospital; Indonesia: Database of Cipto Mangunkusumo Hosp
PMID 18304459; Korea: PMID 18158028; India: PMID 25109719.factor. Based on current governmental spending on health-
care, PSA-based screening would probably not be launched
in the near future for the majority of Asian countries.
4.2. Age-specific PSA cut-off value for Asian
countries
As it has been shown, the PSA level in Asian populations is
reported to be lower than that of Western populations [25].selected Asian countries and regions. Data sources: Mainland,
Kong, China: from HKU (Hong Kong University) and CUHK (The
obotic Transperineal Biopsy of Prostate Database of Singapore
ital, Faculty of Medicine University of Indonesia. Macau, China:
Prostate cancer in Asia 21Age-specific cut-offs have been established for Japanese,
Chinese, Indians, Koreans, and Malays [26]. Reported age-
specific cut-off values have been summarized in Table 2
[25e38]. In general, these cut-off values are higher than
that of the Western population, but there are some dif-
ferences within these countries. For instance, the cut-off
values of Malays and Arabians seem to be lower
compared with Eastern Asians. In a clinical scenario such
consideration should be noted and more importantly,
healthcare policy-makers should acknowledge such
differences.4.3. Distribution of men who underwent prostate
biopsies in different PSA categories
As screening programs in the Western population have led
to an increase in the PCa incidence rate starting from the
1990s, PCa patients were diagnosed at a much earlier
stage, with most of the patients having a PSA level under
20 ng/mL. In a clinical setting, patients diagnosed in Asian
countries such as China and Japan are of an older age with a
higher PSA level [39,40]. In fact, with the joint efforts of
participating urology centers, we confirmed the pattern of
PSA distribution of patients who underwent biopsies in
different Asian countries and further illustrated the char-
acteristics of specific countries (Fig. 2).Figure 3 Prostate cancer detection rate of patients with diffe
Indonesia: Hospital data, Cipto Mangunkusumo Hospital, Faculty
Robotic Transperineal Biopsy of Prostate Database of Singapore Gen
from HKU (Hong Kong University) and CUHK (The Chinese University
PMID 25109719; Korea: PMID 18158028; Macau, China: PMID 18304
Turkey: An Epidemiological Study, Accepted for publication in the
2014).4.4. PCa detection rate in different PSA categories
in different countries
The relationship between detection rate of PCa and PSA
levels has been reported to vary distinctively in different
countries [41]. In the Asian population, the detection rate
of PCa has been shown to be much lower in the diagnostic
gray zone of PSA 4e10 ng/mL. Here, we illustrated the
detection rate of PCa in this PSA range in different pop-
ulations of Asia (Fig. 3).
As is shown, although the data sources vary in different
countries, a distinct difference lies in the detection rate of
PCa between Asians and the Western population [42]. The
detection rate is below 25% in most reports except for
Macau, China due to the limited number of cases and
Turkey mostly Caucasian, which is why they are an excep-
tion. The differences in the detection rates indicated
strong racial differences and provided further evidence
against the universal pattern of using PSA as a screening
tool in these populations.
Recently, it has been reported that genetic factors may
play in role in the differences of PSA levels between Asians
and Western populations. A GWAS in the Japanese popula-
tion [43] illustrated that SNP rs16856139 is significantly
associated with the levels of PSA in the Japanese popula-
tion, yet the genetic differences in PSA levels between
different populations are yet to be unveiled.rent PSA levels in Asian countries and regions. Data sources:
of Medicine University of Indonesia. (2011e2013); Singapore:
eral Hospital; Taiwan, China: PMID 9610567; Hong Kong, China:
of Hong Kong) university hospitals; Japan: PMID 9861233; India:
459; Turkey: Ferruh Zorlu et al., Prostate Cancer Incidence in
Asian Pacific Journal of Cancer Prevention, Vol 15 (August 19,
Figure 4 Gleason score of prostate cancer patients at diagnosis in Asian countries and regions. Data sources: Macau, China: PMID
18304459; Turkey: Ferruh Zorlu et al., Prostate Cancer Incidence in Turkey: An Epidemiological Study, Accepted for publication in
the Asian Pacific Journal of Cancer Prevention, Vol 15 (August 19, 2014); Kuwait: Database of Mubarak Al-Kabeer Teaching Hospital,
Kuwait; Hong Kong, China: from HKU (Hong Kong University) and CUHK (The Chinese University of Hong Kong) university hospitals;
Singapore: Cancer Registry Singapore General Hospital; Taiwan, China: PMID 17482934; Indonesia: Hospital data, Cipto Man-
gunkusumo Hospital, Faculty of Medicine University of Indonesia (2011e2013).
22 R. Chen et al.4.5. Tumor grade and stage at diagnosis
With the application of the PSA tests and PSA-based
screening in Western countries, there has been a signifi-
cant trend of stage migration and a lower Gleason Score in
patients at the time of diagnosis. In Asian countries/regions
with more developed economic and healthcare situations,
there are more patients with early stages and favorable
Gleason Scores (Japan, Korea, Singapore, etc.) (Figs. 4, 5A).
However, the majority of patients in China are still diag-
nosed with high-grade PCa (Gleason Score > 7). PCa of Asian
populations generally display a high likelihood of advanced
clinical stages compared to Western populations. Similar to
that of Western countries, in developing counties of Asia
such as China, there is also an emerging trend towards early
stages at diagnosis (Fig. 5B). In regions with developed
economic environment, such as Hong Kong, Turkey, and
Singapore, the rate of localized PCa accounts for more than
half of the diagnosed patients (Fig. 5A). However, there are
more than 20% of patients diagnosed with metastatic dis-
ease in China and only about 40% patients were diagnosed
with localized PCa who are favorable to undergo surgical
treatments. However, this situation seems to change in
recent years as more patients are diagnosed with localized
disease in CPCC hospitals than before (Fig. 5B).4.6. Emerging novel biomarkers
Currently, a couple of novel biomarkers for PCa have been
approved by the United States Food and Drug Administra-
tion (FDA). PCa antigen 3 (PCA3) is a long non-coding RNAthat is highly expressed specifically in PCa tissue. It has
been approved to help decision-making in repeat biopsies
[44]. PSA isoform [-2]proPSA (p2psa) is an isoform of serum
PSA with the ability to discriminate positive and negative
biopsies. P2psa and its derivatives %p2psa and Prostate
Health Index (PHI) have proven to be effective in discrim-
inating PCa patients from negative biopsies [45]. Although
both biomarkers have been validated in Caucasians, their
effectiveness must be validated in Asian population before
they can be put to clinical use.
The validation studies have been carried out in the Asian
populations [44,46e53]. Although PCA3 and p2psa have
achieved a comparable diagnostic accuracy with Western
reports, their diagnostic accuracy is still limited in patients
with PSA of 4e10 ng/mL. On the other hand, as the
TMPRSSEGR fusion varies significantly amongdifferent races,
the lesson it has taught us is that all these biomarkers may
vary among ethnicities and there may be better biomarkers
for Asian populations as well. In this regard, Asian urologists
also performed some pilot studies (Table 3). Biomarkers
including metastasis associated in lung adenocarcinoma
transcript 1 (MALT-1) [54], genetic score based on SNPs [55],
polypeptide neurotransmitter polypeptide neuropeptide-Y
(NPY) [56] and serum zinc [57] have been tested as diag-
nostic and risk stratification biomarkers.
A fragment of MALAT-1, named MD-miniRNA, has proved
to be stable in plasma. This fragment has been validated to
differentiate PCa and non-PCa patient at a cut-off of 867.8
MD-miniRNA copies per microliter of plasma with the
sensitivity of 56.6% and specificity of 84.8% in discrimi-
nating PCa patients from non-PCa patients. This is the first
time anyone has been able to test fragments of long non-
Figure 5 Stages of diagnosed prostate cancer in (A) Asian countries and regions; (B) Chinese Prostate Cancer Consortium hos-
pitals in past 6 years. Data sources: Turkey: Ferruh Zorlu et al., Prostate Cancer Incidence in Turkey: An Epidemiological Study,
Accepted for publication in the Asian Pacific Journal of Cancer Prevention, Vol 15 (August 19, 2014); Japan: Jpn J Clin Oncol 2014
Aug 6. pii: hyu104. (Epub ahead of print); Singapore: Cancer Registry Singapore General Hospital; Macau, China: 55.1% for localized
PCa, 30.5% for non-localized PCa and 14.4% not available. PMID 18304459; CPCC: CPCC member hospitals statistics; Hong Kong,
China: from HKU (Hong Kong University) and CUHK (The Chinese University of Hong Kong) university hospitals; Taiwan, China: PMID
17482934; Indonesia: Hospital data, Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia. (2011e2013);
Kuwait: Database of Mubarak Al-Kabeer Teaching Hospital, Kuwait.
Prostate cancer in Asia 23coding RNA in plasma to diagnose diseases. Recently, this
approach to diagnose disease has also been validated in
patients of gastric cancer [58], illustrating the viability of
this approach. Other approaches in identifying novel bio-
markers for Asian PCa detection included SNPs, polypeptide
and other molecules with promising results [55e57].However, research on biomarkers in Asian countries is still
behind in both the number of studies and the quality of
research compared with Western countries. Because of the
heterogenetic nature of PCa, it is predictable that
biomarker research will be on a rising trend in Asian
population.
Table 3 Validation of biomarkers found in the Western population and biomarker research in Asian countries and regions.
Biomarker Property Indication Ethnic Study Ref. Cases AUC Cut-off Sen. Spe.
PCA3 Urine long
non-coding RNA
Repeat biopsy Multicentric
European
Haese et al.,
2008
[44] 463 0.658 35.0 47.0 72.0
Initial biopsy Italian Lazzeri et al.,
2013
[47] 1026 0.733 1.7 70.4 70.1
All biopsy Japanese Ochiai et al.,
2011
[48] 105 NA 35.0 74.3 74.6
Initial biopsy Japanese Ochiai et al.,
2013
[49] 633 0.742 35.0 66.5 71.6
Initial biopsy Chinese
(Hong Kong)
Ng et al.,
2012
[50] 149 NA 35.0 92.0 71.0
Initial biopsy Chinese Shen et al.,
2010
[51] 102 0.786 0.107
(Real-Time
PCR)
62.9 90.6
PHI p2PSA/free
PSA  ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃtPSAp
Initial biopsy PSA
2.0e10.0 ng/mL
Italian Guazzoni
et al., 2011
[45] 268 0.76 48.5 90.0 42.9
Initial biopsy PSA
2.0e10.0 ng/mL
Chinese Na et al.,
2013
[52] 636 0.73
Initial biopsy PSA
4e10 ng/mL
Chinese
(Hong Kong)
Ng et al.,
2014
[53] 230 0.781 26.5 90.0 45.2
Initial biopsy PSA
2.0e10.0 ng/mL
Japanese Ito et al.,
2013
[54] 239 NA 23.9 90.0 28.0
MALAT-1 Plasma long
non-coding RNA
Initial biopsy PSA
4e10 ng/mL
Chinese Ren et al.,
2013
[55] 192 0.767 867.8 43.5 81.6
Genetic
score
13 PCa associated
SNPs
Initial biopsy
(All PSA range)
Chinese Jiang et al.,
2013
[56] 667 0.63 1.5 52.0 52.0
NPY Neurotransmitter
polypeptide
neuropeptide-Y
Pilot study
(All PSA range)
Japanese Ueda et al.,
2013
[57] 110 0.717 5189.0 41.5 97.8
Serum
zinc
Metal ion Pilot study
(PSA 4e10 ng/mL)
Chinese Li et al., 2005 [58] 85 0.73 100.0 90.5 32.7
PCA3, prostate cancer antigen 3; PHI, prostate health index; Real-Time PCR, real-time polymerase chain reaction; PSA, prostate-specific
antigen; MALAT-1, metastasis associated in lung adenocarcinoma transcript; SNPs, single nucleotide polymorphisms; p2PSA: [-2]proPSA;
Ref., reference; AUC, area under the curve; Sen., sensitivity; Spe., specificity. NA: not available.
Figure 6 Changes of prostatectomy type in Prostate Cancer
Consortium hospitals from 2006 to 2013. Data sources: CPCC
member hospitals data. RALP, robotic-assisted radical prosta-
tectomy; LRP, laparoscopic radical prostatectomy; RRP, ret-
ropubic radical prostatectomy.
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5.1. Changes in approach of prostatectomy in Asia
Radical prostatectomy (RP) is a standard treatment option
for patients with localized PCa. RP can be performed by
either retropubic radical prostatectomy (RRP) or laparo-
scopic radical prostatectomy (LRP). Anatomic RRP was first
performed by Professor Walsh in 1979 [59]. However at that
time, few institutes in Asian countries focused their
research on PCa. Even the first review of PCa in Japan was
only published in 1983. In China, the first anatomic pros-
tatectomy surgeries were performed around the middle of
the 1990s.
LRP was first performed in 1992 and received more
attention until reported by Schuessler et al. [60]. This time,
Asian urologists caught up with this trend relatively faster.
A search in the PubMed and CNKI (China National Knowl-
edge Infrastructure) database indicated the first reported
LRP from Japan and China was in 2001 and 2002, respec-
tively [61,62].
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was performed in 2000 by Binder et al. from Frankfurt [63].
RALP was performed in Asian countries from as early as
2003 in Singapore and 2004 in Taiwan, China. In Mainland
China, the first RALP was performed in 2007 by Gao et al.
[64]. The time span between the application of RALP be-
tween Western and Asian urologists has been shorted to
only a couple of years. From anatomic RRP to LRP and from
LRP to RALP, it is clear that Asian urologists are catching up
in surgery methods and the time span between the first
cases has shortened.
Once again with the collaboration of CPCC members, the
current status of the percentage of each surgery approach
has been summarized (Fig. 6). One other thing to note is
that the data came from both a national level and the
representative hospital (in case of failure to obtain a na-
tional figure). As is illustrated, the proportion of RRP is
reduced whereas LRP takes the largest proportion in the 20
hospitals in CPCC. Although there is a substantial increase
in the number of RALP, the proportion of RALP is still fairly
low as only three out of 20 hospitals are equipped with da
Vinci systems.Table 4 Cumulative number of da Vinci Systems in Asian
countries and regions.
Country 2010 2011 2012 2013
Japan 32 40 80 159
Korea 28 36 38 44
Mainland, China 10 13 15 18
Taiwan, China 4 10 15 20
India 6 17 19 20
Hong Kong, China 7 7 8 8
Singapore 3 6 7 7
Malaysia 1 3 3 3
Thailand 0 1 4 6
Philippines 0 1 1 2
Indonesia 0 0 1 1
Total 108 134 191 288
Data sources: Intuitive Surgical Inc., Shanghai, China.5.2. Current status of the effectiveness of
prostatectomy in Asia
Although RPwas adopted late in Asia and the number of cases
is much smaller compared with Western countries, Asian
surgeons have quickly adapted RP techniques. Asian reports
of RP results indicated a comparable outcome in terms of
preservation of both continence and sexual function to
Western reports [65,66]. In recent years, an increasing
number of urologists are not satisfied with just completing
the surgery itself but also aimed to achieve the trifecta of RP
(cancer free, potency and continence). More approaches
have been developed and validated to be viable. For
instance, Single-port LRP was preferred by Wen et al. [67]
and has been shown to achieve better results in selected
patients. Extraperitoneal LRP was preferred by Zheng et al.
[66] for its advantages in preventing intra-abdominal com-
plications and combined the advantages of minimally inva-
sive laparoscopy and retropubic open prostatectomy.
There are now several high-volume centers for RP with a
well-designed follow-up system that makes the long-term
assessment of the surgery result possible in developed
countries such as Japan, Korea, Israel and developing
countries such as China and India. For instance, Namiki
et al. [68] reported the long-term follow-up data for 91
patients in a median follow-up of 102 months. Mishra et al.
[69] reported the oncological outcome of LRP in a median
follow-up of 6 years. Koo et al. [70] reported a comparison
study of RALP and open radical prostatectomy in 1172 pa-
tients with a mean follow-up time of 58.4 months. Their
result indicated that RALP is as good as open RP in terms of
oncological outcomes. Considering the relatively large
population in Asia, the number of RP cases is expected to
increase fast and there would be more opportunities for
urologists to investigate the unique characteristics of RP in
Asian men with its own anatomical characteristics.
Furthermore, urologists in Asia also developed some
innovative work in RP. Gao et al. [71] performed the firstseries of single-port transvesical LRP with promising func-
tional outcomes regarding continence and potency.
Another innovative approach in RALP is that Korean urolo-
gists reported the comparison of Retzius-sparing RALP with
conventional RALP [72]. Retzius-sparing RALP was consid-
ered as not practical in the past, however, Lim et al. [72]
confirmed it would reduce operating time and help to
achieve a faster recovery of early continence.
However, it must be recognized that the advances in RP
are still limited in Asia when compared with developed
Western countries, regardless of the number of cases and
techniques. In 2013, the 10th European Conference in
Laparoscopic Robotic Surgery in Urology was held in Beijing,
China. Well-organized academic meetings would facilitate
the communication between urologists in Asia and other
countries.5.3. Trend of robotic-assisted radical
prostatectomy in Asia
In recent years, RALP has gained popularity globally with
advantages to both patients and urologists. The benefit for
patients includes less blood loss, less pain and shorter
hospital stay. The benefits for urologists are improved er-
gonomics, with accurate three-dimensional display, and the
ease of use of maneuverable robotic instruments [73].
The literature has shown that RALP had a short learning
curve and promising postoperative results, especially with
regard to continence recovery [73]. RP is the most common
robotically assisted surgical procedure performed in the
United States. Reported 5-year biochemical failure-free
survival for RALP ranges from 83.3% to 87%, which is bet-
ter than open RP [73].
The major downside of RALP is the cost. In an ideal
scenario, most urologists would be inclined to use this novel
technique, but the reality is that the high cost of RALP is
often hard to accept by patients in developing countries in
Asia, especially when the governmental insurance covers a
small or no proportion of the costs of surgery. As is illus-
trated, the number of da Vinci systems is surging in
developed countries such as Japan and Korea but are
Table 5 Newly FDA-approved agents for CRPC in Asia.
Agent Mechanism FDA
approval
Clinical trials
in Asia
Clinical trials
in USA
Availability on market
Enzalutamide Androgen receptor inhibitor 2012 11 48 Korea, Hong Kong, Japan
Abiraterone Androgen biosynthesis inhibitor 2011 20 74 Singapore, Hong Kong, India,
Indonesia, Israel, Japan,
Jordan, Korea, Kuwait,
Malaysia, Saudi Arabia,
Taiwan, Turkey
Cabazitaxel Novel taxane chemotherapy 2010 12 20 Singapore, Japan, Turkey,
Taiwan, Indonesia
Sipuleucel-T Autologous immunotherapeutic
agent
2010 0 26 NA
Radium 223 Alpha particle-emitting
radiopharmaceutical
2013 11 13 Korea, Singapore
Data sources: www.clinicaltrials.gov, searched on Aug 31, 2014.
26 R. Chen et al.difficult to find in most other Asian countries at the moment
(Table 4). RALP is starting to take its momentum in Main-
land China, Turkey and Taiwan (China) in recent years,
while Japan has already out-weighted the total number of
other Asian countries (Data source: Intuitive Surgical Inc.,
Shanghai, China). It is predicted that the number of RALP
will likely keep this momentum with increases in number of
cases in existing centers and the establishment of new da
Vinci centers.6. Novel agents for CRPC
The prognosis of CRPC patients is rather unfavorable with
an overall survival time of 24e36 months [74]. Prior to
2010, the treatment options for CRPC were limited. In theFigure 7 Number of completed and on-going clinical trials of five
clinicaltrials.gov/, searched on Aug 31, 2014.past 3 years, US FDA approved five new agents for CRPC
(Table 5). These agents not only expanded the arsenal
against CRPC but also enlightened the hope for patients
with advanced prostate cancer. Currently, all of these
agents are recommended by the AUA guidelines for PCa in
different conditions. In Asian countries, with the joint ef-
forts of manufacturers and clinical oncologists, clinical
trials have been started in recent years (Fig. 7). Hopefully,
with these new agents, patients will have a longer
progression-free survival as well as an improved overall rate
of survival. However, as there are two sides to every sword,
the emergence of these new drugs are beneficial to pa-
tients with proper indications but may not always be
helpful to the developing Asian countries that already have
limited budget for cancer control. In this aspect, both the
manufacture and the healthcare ministry of these countriesnovel agents for CRPC worldwide. Data sources: http://www.
Figure 8 Prostate-cancer-related research papers by countries. Data sources: http://www.ncbi.nlm.nih.gov/pubmed, searched
on Aug 31, 2014.
Prostate cancer in Asia 27should make individualized policies for each country in
order to achieve a winewin situation for all. Currently,
there is no leading innovative pharmaceutical research
group in Asian countries that could pave the way forward
for novel CRPC agents.
7. Prospective
As incidence and mortality rates have continued to increase
during the past decades and a trend towards an older pop-
ulation as well as a more Western lifestyle, PCa has now
become one of the most prevalent malignancies in Asian
countries. A recent autopsy study revealed that incidence of
PCa is rather similar in Japanese and Russians [75]. Thus, if
the Western strategy of management of PCa is introduced in
Asia, it is possible that manymore patients will be diagnosed
with PCa in Asia. With joint efforts from urologists and re-
searchers across Asia, research of PCa has been surging with
more clinical and research articles being published (Fig. 8).
With such scientific developments, the management of PCa
in diagnosis and treatment has also been improving greatly. It
is expected that Asian researchers and urologists will gain a
better understanding of prostate cancer in their own coun-
tries and find better ways to combat this disease uniquely.
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